25437-95-0

Basic information

• Product Name: Benzoic acid, 4-(4-oxo-1-piperidinyl)-, ethyl ester
• Synonyms: Benzoic acid, 4-(4-oxo-1-piperidinyl)-, ethyl ester;ethyl 4-(4-oxopiperidin-1-yl)benzoate
• CAS NO: 25437-95-0
• Molecular Formula: C₁₄H₁₇NO₃
• Molecular Weight: 247.28968
• Mol File: 25437-95-0.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Benzoic acid, 4-(4-oxo-1-piperidinyl)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(4-oxo-1-piperidinyl)-, ethyl ester(25437-95-0)
• EPA Substance Registry System: Benzoic acid, 4-(4-oxo-1-piperidinyl)-, ethyl ester(25437-95-0)

Safety Data

• Hazardous Substances Data: 25437-95-0(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 4-(4-oxo-1-piperidinyl)-, ethyl ester is a chemical compound with the molecular formula C14H19NO3. It is a synthetic organic compound with potential use as a pharmaceutical intermediate. Benzoic acid, 4-(4-oxo-1-piperidinyl)-, ethyl ester is a piperidine derivative, containing a benzoic acid moiety and an ethyl ester group. It is commonly used in the pharmaceutical industry for the synthesis of various drugs and can also be used as a building block for the synthesis of other organic compounds. Benzoic acid, 4-(4-oxo-1-piperidinyl)-, ethyl ester has the potential to exhibit various pharmacological activities and is an important intermediate in the production of pharmaceuticals.

Upstream product

• 177-11-7 4,4-ethylenedioxy-piperidine 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 79421-38-8 4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-benzoic acid ethyl ester 
• 25437-94-9 ethyl 4-(4-hydroxypiperidin-1-yl)benzoate 

Downstream Products

• 169032-01-3 (1R)-2-amino-1-(3-chloro-phenyl)-ethanol hydrochloride 
• 406233-70-3 ethyl 4-(4-methylenepiperidin-1-yl)benzoate 
• 116248-02-3 4-(10-chloro-3,4-dihydrobenzo[b][1,6]-naphthyridin-2(1H)-yl)benzoic acid ethyl ester 
• 1235865-62-9 ethyl 4-(4-((4'-chlorobiphenyl-2-yl)methylene)piperidin-1-yl)benzoate 
• 1449429-06-4 ethyl 4-(2-amino-3-cyano-4,5-dihydrothieno[2,3-c]pyridin-6(7H)-yl)benzoate 
• 1132838-19-7 ethyl 4-(4-(2-bromobenzylamino)piperidin-1-yl)benzoate 
• 1132838-12-0 ethyl 4-(4-(benzylamino)piperidin-1-yl)benzoate 
• 95017-71-3 1-<4-(ethoxycarbonyl)phenyl>3-(2,2-dicyanovinyl)-4-(N-pyrrolidino)-1,2,5,6-tetrahydropyridine 
• 95017-75-7 2,4-diamino-7-<4-(ethoxycarbonyl)phenyl>-5-deaza-6,7,8,9-tetrahydropyrido<3,4-g>pteridine 
• 95017-73-5 2-amino-3-cyano-6-<4-(ethoxycarbonyl)phenyl>-5,6,7,8-tetrahydropyrido<4,3-b>pyridine 

Relevant articles and documents

Structure-activity relationships of new cyanothiophene inhibitors of the essential peptidoglycan biosynthesis enzyme MurF

Peptidoglycan is an essential component of the bacterial cell wall, and enzymes involved in its biosynthesis represent validated targets for antibacterial drug discovery. MurF catalyzes the final intracellular peptidoglycan biosynthesis step: the addition of D-Ala-D-Ala to the nucleotide precursor UDP-MurNAc-L-Ala-γ-D-Glu-meso-DAP (or L-Lys). As MurF has no human counterpart, it represents an attractive target for the development of new antibacterial drugs. Using recently published cyanothiophene inhibitors of MurF from Streptococcus pneumoniae as a starting point, we designed and synthesized a series of structurally related derivatives and investigated their inhibition of MurF enzymes from different bacterial species. Systematic structural modifications of the parent compounds resulted in a series of nanomolar inhibitors of MurF from S. pneumoniae and micromolar inhibitors of MurF from Escherichia coli and Staphylococcus aureus. Some of the inhibitors also show antibacterial activity against S. pneumoniae R6. These findings, together with two new co-crystal structures, represent an excellent starting point for further optimization toward effective novel antibacterials.

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

BCL-2 INHIBITORS

The present invention relates to Bcl-2 inhibitors and their use in the treatment of cell proliferative diseases such as cancer.